OpenURL Connection Search

Select item for more details and to access through your institution.

ZAP-70 is highly expressed in most cases of childhood pre-B cell acute lymphoblastic leukemia.
Published in:
2008
By:
- Wandroo F;
- Bell A;
- Darbyshire P;
- Pratt G;
- Stankovic T;
- Gordon J;
- Lawson S;
- Moss P
Publication type:
Journal Article
ZAP-70 is highly expressed in most cases of childhood pre-B cell acute lymphoblastic leukemia.
Published in:
International Journal of Laboratory Hematology, 2008, v. 30, n. 2, p. 149, doi. 10.1111/j.1751-553X.2007.00915.x
By:
- WANDROO, F.;
- BELL, A.;
- DARBYSHIRE, P.;
- PRATT, G.;
- STANKOVIC, T.;
- GORDON, J.;
- LAWSON, S.;
- MOSS, P.
Publication type:
Article
SARS-2 COVID-19-induced immunity response, a new prognostic marker for the pregnant population correlates inversely with neonatal Apgar score.
Published in:
Infection, 2022, v. 50, n. 5, p. 1121, doi. 10.1007/s15010-022-01773-3
By:
- Marwah, M.;
- Shokr, H.;
- Demitry, A.;
- Wang, K.;
- Ahmad, S.;
- Marwah, S.;
- Wandroo, F.
Publication type:
Article
Successful use of Campath-1H in the treatment of steroid refractory liver GvHD.
Published in:
2004
By:
- Wandroo, F.;
- Auguston, B.;
- Cook, M.;
- Craddock, C.;
- Mahendra, P.
Publication type:
Letter
THROMBOSIS IN COVID-19: REVIEW AND GUIDANCE FOR CLINICIANS.
Published in:
JK Practitioner, 2020, v. 25, n. 1-4, p. 53
By:
- Farooq, S.;
- Wandroo, F. A.
Publication type:
Article
BRIEF CO‐ADMINISTRATION OF IDELALISIB MAY IMPROVE THE LONG‐TERM EFFICACY OF FRONTLINE CHEMOIMMUNOTHERAPY IN CHRONIC LYMPHOCYTIC LEUKAEMIA: 3‐YEAR FOLLOW‐UP FROM THE RIALTO TRIAL.
Published in:
Hematological Oncology, 2019, v. 37, p. 217, doi. 10.1002/hon.32_2630
By:
- Pettitt, A.;
- Kalakonda, N.;
- Cicconi, S.;
- Murphy, C.;
- Menon, G.;
- Coupland, S.E.;
- Oates, M.;
- Lin, K.;
- Pocock, C.;
- Jenkins, S.;
- Schuh, A.;
- Wandroo, F.;
- Rassam, S.;
- Duncombe, A.S.;
- Cervi, P.;
- Paneesha, S.;
- Aldouri, M.;
- Fox, C.;
- Knechtli, C.;
- Hamblin, M.
Publication type:
Article
BRIEF CO‐ADMINISTRATION OF IDELALISIB MAY IMPROVE THE LONG‐TERM EFFICACY OF FRONTLINE CHEMOIMMUNOTHERAPY IN CHRONIC LYMPHOCYTIC LEUKAEMIA: 3‐YEAR FOLLOW‐UP FROM THE RIALTO TRIAL.
Published in:
Hematological Oncology, 2019, v. 37, p. 217, doi. 10.1002/hon.32_2630
By:
- Pettitt, A.;
- Kalakonda, N.;
- Cicconi, S.;
- Murphy, C.;
- Menon, G.;
- Coupland, S.E.;
- Oates, M.;
- Lin, K.;
- Pocock, C.;
- Jenkins, S.;
- Schuh, A.;
- Wandroo, F.;
- Rassam, S.;
- Duncombe, A.S.;
- Cervi, P.;
- Paneesha, S.;
- Aldouri, M.;
- Fox, C.;
- Knechtli, C.;
- Hamblin, M.
Publication type:
Article
EFFECT OF ADDING IDELALISIB TO FRONTLINE OFATUMUMAB PLUS EITHER CHLORAMBUCIL OR BENDAMUSTINE IN LESS FIT PATIENTS WITH CLL: PRELIMINARY RESULTS FROM THE NCRI RIALTO TRIAL.
Published in:
Hematological Oncology, 2017, v. 35, p. 88, doi. 10.1002/hon.2437_77
By:
- Pettitt, A.R.;
- Kalakonda, N.;
- Polydoros, F.;
- Bickerstaff, M.;
- Menon, G.;
- Coupland, S.E.;
- Oates, M.;
- Lin, K.;
- Pocock, C.;
- Jenkins, S.;
- Schuh, A.;
- Wandroo, F.;
- Rassam, S.;
- Duncombe, A.S.;
- Jenner, M.;
- Cervi, P.;
- Paneesha, S.;
- Aldouri, M.;
- Fox, C.P.;
- Knechtli, C.
Publication type:
Article
Cutaneous necrosis in a young woman.
Published in:
Clinical & Experimental Dermatology, 2007, v. 32, n. 2, p. 231, doi. 10.1111/j.1365-2230.2006.02311.x
By:
- Wandroo, F. A.;
- Rose, P.;
- Sinha, B.
Publication type:
Article

Found: 9